Article (Scientific journals)
Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn's disease stopping infliximab: when the remission state hides different types of residual disease activity.
Pierre, Nicolas; Huynh-Thu, Vân Anh; Marichal, Thomas et al.
2022In Gut, p. 2022-327321
Peer Reviewed verified by ORBi
 

Files


Full Text
AAM_Gut_2022.pdf
Author postprint (1.74 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Crohn's disease; clinical decision making; infliximab; Gastroenterology
Abstract :
[en] OBJECTIVE: Despite being in sustained and stable remission, patients with Crohn's disease (CD) stopping anti-tumour necrosis factor α (TNFα) show a high rate of relapse (~50% within 2 years). Characterising non-invasively the biological profiles of those patients is needed to better guide the decision of anti-TNFα withdrawal. DESIGN: Ninety-two immune-related proteins were measured by proximity extension assay in serum of patients with CD (n=102) in sustained steroid-free remission and stopping anti-TNFα (infliximab). As previously shown, a stratification based on time to clinical relapse was used to characterise the distinct biological profiles of relapsers (short-term relapsers: <6 months vs mid/long-term relapsers: >6 months). Associations between protein levels and time to clinical relapse were determined by univariable Cox model. RESULTS: The risk (HR) of mid/long-term clinical relapse was specifically associated with a high serum level of proteins mainly expressed in lymphocytes (LAG3, SH2B3, SIT1; HR: 2.2-4.5; p<0.05), a low serum level of anti-inflammatory effectors (IL-10, HSD11B1; HR: 0.2-0.3; p<0.05) and cellular junction proteins (CDSN, CNTNAP2, CXADR, ITGA11; HR: 0.4; p<0.05). The risk of short-term clinical relapse was specifically associated with a high serum level of pro-inflammatory effectors (IL-6, IL12RB1; HR: 3.5-3.6; p<0.05) and a low or high serum level of proteins mainly expressed in antigen presenting cells (CLEC4A, CLEC4C, CLEC7A, LAMP3; HR: 0.4-4.1; p<0.05). CONCLUSION: We identified distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with CD stopping infliximab. These findings constitute an advance for the development of non-invasive biomarkers guiding the decision of anti-TNFα withdrawal.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Pierre, Nicolas  ;  Université de Liège - ULiège > GIGA > GIGA I3 - Translational gastroenterology
Huynh-Thu, Vân Anh ;  Université de Liège - ULiège > Département d'électricité, électronique et informatique (Institut Montefiore) > Algorithmique des systèmes en interaction avec le monde physique
Marichal, Thomas  ;  Université de Liège - ULiège > GIGA
Allez, Matthieu ;  Service d'Hépato-Gastroentérologie, Hôpital Saint Louis, APHP, Université de Paris, Paris, France
Bouhnik, Yoram;  Service de Gastroentérologie et Assistance Nutritive, Hôpital Beaujon, Clichy, France
Laharie, David ;  Service d'Hépato-Gastroentérologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
Bourreille, Arnaud;  Institut des maladies de l'appareil digestif, Centre Hospitalier Universitaire de Nantes, Nantes, France
Colombel, Jean-Frédéric;  Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
Meuwis, Marie-Alice  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive
Louis, Edouard  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive
GETAID (Groupe d’Etude Thérapeutique des Affections Inflammatoires du tube Digestif)
Language :
English
Title :
Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn's disease stopping infliximab: when the remission state hides different types of residual disease activity.
Publication date :
25 August 2022
Journal title :
Gut
ISSN :
0017-5749
eISSN :
1468-3288
Publisher :
BMJ, England
Pages :
gutjnl-2022-327321
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
ULiège - University of Liège [BE]
CHU Liège - Centre Hospitalier Universitaire de Liège [BE]
Available on ORBi :
since 29 September 2022

Statistics


Number of views
300 (35 by ULiège)
Number of downloads
408 (4 by ULiège)

Scopus citations®
 
7
Scopus citations®
without self-citations
6
OpenCitations
 
0

Bibliography


Similar publications



Contact ORBi